Zephyr AI Funding, Investors & Competitors

Zephyr AI has raised $130M across 2 funding rounds, most recently a $111M Series A in March 2024.

Last Zephyr AI funding round

$111M

Series A · Mar 2024

Cumulative funding Zephyr AI raised

$130M

across 2 funding rounds

Key investors in Zephyr AI

  • Liquid 2 Ventures
  • BoxGroup
  • AME Cloud Ventures
  • Revolution Growth
  • EPIQ Capital Group
  • Eli Lilly & Company Foundation
  • Lerner Enterprises
  • MedStar Health

Zephyr AI Overview

About Zephyr AI

Zephyr AI is an Austin-headquartered healthcare AI company accelerating drug discovery and precision medicine. The platform analyzes multimodal patient data from electronic health records and genomics to identify novel targets and biomarkers. Zephyr AI partners with biopharma firms like Pfizer and health systems such as Mayo Clinic to validate therapies in oncology and cardiology. Its knowledge graph integrates real-world evidence for clinical trial optimization and personalized treatment recommendations.


Founded

2020

HQ

United StatesWashington, VA

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Zephyr AI Funding History

Zephyr AI has raised a total of $130M across 2 funding rounds.

Zephyr AI's first fundraising round was a $19M seed round in March 2022. The most recent completed round was a $111M Series A in March 2024.

Zephyr AI funding rounds

Zephyr AI funding rounds
DateStageInvestorsRaisedDeal Summary
Mar 2024Series AEli Lilly & Company Foundation (lead); EPIQ Capital Group (lead); Jeff Skoll (lead); Revolution Growth (lead)$111MZephyr AI, a McLean, Virginia-based healthcare technology company founded in 2020 or 2021, develops fast and explainable AI solutions to democratize precision medicine, focusing on oncology and cardiometabolic diseases. The company curates comprehensive healthcare datasets through partnerships and proprietary sources, merging them with machine learning algorithms to generate insights for drug development, clinical trials, clinical decision support, patient stratification, and response predictions. It emphasizes data federation tools to handle real-world patient data and representation learning for biological context in predictions. On March 13, 2024, Zephyr AI closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, EPIQ Capital Group, and about 30 other investors. The round, which began in October 2023, followed a $18.5 million seed round in March 2022 led by Red Cell Partners. Proceeds will enhance analytical speed, expand training and validation datasets, and grow scientific and commercial teams to accelerate delivery of its pipeline of insights. Zephyr AI had two abstracts accepted at the American Association for Cancer Research (AACR) annual meeting in San Diego, April 5-10, 2024, showcasing emerging scientific insights. Leaders like Co-Founder/Interim CEO/CTO Jeff Sherman and Executive Chairman Grant Verstandig highlighted the funding's role in transforming precision medicine and clinical trial outcomes. The investment aligns with surging interest in AI-driven deep tech for healthcare, where Zephyr AI positions itself at the forefront by addressing challenges in real-world data navigation and providing translatable insights for approved medicines and drugs in development.
Mar 2022SeedLerner Enterprises (lead); M-Cor Holdings (lead); MedStar Health; Liquid 2 Ventures; BoxGroup; Allen Chao; AME Cloud Ventures$19MZephyr AI is a healthcare technology company founded in 2020 and based in the McLean/Tysons Corner/Fairfax Station area of Virginia, specializing in AI-driven precision medicine, drug discovery, drug rescue, and clinical decision support using large complex data and proprietary algorithms. The company partners with health systems, insurance plans, and biotech firms to improve outcomes, costs, and quality in areas like oncology, clinicogenomics, real-world evidence, and predictive biomarkers. It develops interpretable AI solutions for patient stratification, drug sensitivity prediction, clinical trial optimization, and multimodal data analysis in biotechnology and pharmaceuticals. On March 30, 2022, Zephyr AI completed a Seed VC funding round with lead investors Lerner Enterprises and M-Cor Holdings, alongside participants including Allen Chao, AME Cloud Ventures, BoxGroup, Liquid 2 Ventures, and MedStar Health, matching the query details. This was the company's first funding round, preceding later raises. Zephyr AI's next major round was a $111 million Series A on March 13, 2024, led by or involving Revolution Growth, EPIQ Capital Group, Eli Lilly and Company Foundation, Jeff Skoll, and Red Cell Partners, bringing total funding to approximately $129.5M to $148M across 2-3 rounds. The company has grown to 31-74 employees, focusing on AI in healthcare analytics, biomarker discovery, and real-world data cohorts for NSCLC, cardiometabolic outcomes, and immune therapies.

Who has invested in Zephyr AI?

11 investors have backed Zephyr AI across its funding rounds, including Liquid 2 Ventures, BoxGroup, AME Cloud Ventures, Revolution Growth, EPIQ Capital Group and Eli Lilly & Company Foundation.

Lead investors include Eli Lilly & Company Foundation, EPIQ Capital Group, Jeff Skoll, Revolution Growth, Lerner Enterprises and 1 other investor.


Zephyr AI Investors

Investors in Zephyr AI by funding rounds participated
InvestorHQRoundsRoleFirst check
MedStar HealthUnited StatesBaltimore, MD1ParticipantMar 2022
Revolution GrowthUnited StatesUnited States1LeadMar 2024
M-Cor Holdings--1LeadMar 2022
Liquid 2 VenturesUnited StatesSan Francisco, CA1ParticipantMar 2022
BoxGroupUnited StatesNew York City, NY1ParticipantMar 2022
Lerner EnterprisesUnited StatesWashington, DC1LeadMar 2022
Allen ChaoUnited StatesWashington, VA1ParticipantMar 2022
EPIQ Capital GroupUnited StatesSan Francisco, CA1LeadMar 2024
Eli Lilly & Company FoundationUnited StatesIndianapolis, IN1LeadMar 2024

This data is available for Pro users. Sign up to see all 11 Zephyr AI investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Zephyr AI

Zephyr AI has acquired 1 company to date.

Last acquisition by Zephyr AI was on August 26th 2025. Zephyr AI acquired Aster Insights for undisclosed valuation.


Latest Acquisitions by Zephyr AI

Aster Insights
Description
Aster Insights is a Boston-based oncology bioinformatics company that delivers clinical decision support tools integrating genomic sequencing data with patient electronic health records. Its platform analyzes tumor molecular profiles to recommend precision therapies, serving oncologists at major cancer centers including MD Anderson and Memorial Sloan Kettering. Founded in 2019, the firm processes data from over 50,000 patient cases to generate actionable insights on drug response predictions and biomarker discovery.
HQ CountryUnited States
HQ City
-
Deal Date26 Aug 2025
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Zephyr AI acquisitions and their M&A valuation multiples.

Start Free Trial

Zephyr AI Competitors

Zephyr AI competitors include listed companies like IQVIA, IDEXX Laboratories, GE HealthCare and ICON plc, and private ones like Uptake Technologies and Commure.

Public and private companies comparable to Zephyr AI
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Uptake TechnologiesUnited StatesUnited StatesPrivate$100M-$2.3B23.0x
IQVIAUnited StatesUnited StatesPublicly listed$16B$3.4B$44B3.4x
IDEXX LaboratoriesUnited StatesUnited StatesPublicly listed$4.3B$1.5B$40B8.9x
GE HealthCareUnited StatesUnited StatesPublicly listed$21B$3.7B$29B1.8x
ICON plcUnited StatesUnited StatesPublicly listed$8.3B$816M$13B1.9x
CommureUnited StatesSan Francisco, CAPrivate$200M-$7B35.0x

Zephyr AI Public Comps

Zephyr AI is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Palantir, Merck, Roche, Novartis, AstraZeneca, Amgen and Novo Nordisk.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Eli Lilly$65B$28B16.5x13.1x38.7x27.0x
Johnson & Johnson$94B$40B7.2x6.8x17.0x18.3x
AbbVie$61B$17B8.7x8.1x30.6x17.6x
Palantir$4.5B$1.5B92.6x58.1x285.0x97.4x
Merck$65B$28B6.3x6.2x14.7x21.0x
Roche$77B$26B5.0x4.9x14.6x12.4x
Novartis$57B$22B5.5x5.5x14.2x13.3x
AstraZeneca$59B$19B4.8x4.5x14.6x12.7x

This data is available for Pro users. Sign up to see all Zephyr AI competitors and their valuation data.

Start Free Trial

Common questions about Zephyr AI

When was Zephyr AI founded?Zephyr AI was founded in 2020.
Where is Zephyr AI headquartered?Zephyr AI is headquartered in Washington, VA, United States.
Is Zephyr AI publicly listed?No, Zephyr AI is a private, VC-backed company.
How much funding has Zephyr AI raised?Zephyr AI has raised $130M across 2 funding rounds.
What was Zephyr AI's last funding round?Zephyr AI's last funding round was a $111M Series A in March 2024, led by Eli Lilly & Company Foundation, EPIQ Capital Group, Jeff Skoll and Revolution Growth.
Who are Zephyr AI's investors?Zephyr AI's investors include MedStar Health, Revolution Growth, M-Cor Holdings, Liquid 2 Ventures, BoxGroup, Lerner Enterprises, Allen Chao, EPIQ Capital Group, Eli Lilly & Company Foundation, Jeff Skoll and 1 other.
Which companies are comparable to Zephyr AI?Companies comparable to Zephyr AI include Uptake Technologies, IQVIA, IDEXX Laboratories, GE HealthCare, ICON plc and Commure.
How many companies has Zephyr AI acquired?Zephyr AI has acquired 1 company, including Aster Insights.

See companies similar to Zephyr AI

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial